Search

everythinglearnresearchcommunity

for

Search:↓

Certain genetic variants are linked to frontal fibrosing alopecia in Spanish patients.

New cytokine-targeted therapies show promise for treating alopecia areata.

Antigens from skin cells may cause hair loss in perinevoid alopecia.

Human hair shows promise for non-invasive medical testing, but more research is needed to standardize its use.

The document concludes that treatments for cicatricial alopecia are not well-supported by evidence, but hair transplantation shows more predictable and satisfactory results.

Early and aggressive treatment of scarring alopecia is important to prevent further hair follicle damage.

The document concludes that the skin is a complex organ providing protection, sensation, and healing, with challenges in treating conditions like itchiness.

Latanoprost is more effective than minoxidil for treating alopecia areata.

Alopecia areata causes hair loss with varied treatment responses and frequent relapses.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Severe alopecia areata greatly impacts quality of life, mental health, and daily activities.

SH-MSCs gel can effectively treat alopecia by increasing IL-10 and decreasing TNF-α gene expression.

Alopecia areata patients have higher levels of certain immune receptors, suggesting new treatment possibilities.

Oxidative stress is linked to mild patchy alopecia areata.

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

Satoyoshi syndrome is likely an autoimmune disease that mainly affects young women and improves with immune-related treatments.

ILC1-like cells can cause alopecia areata by attacking hair follicles.

Alopecia areata causes patchy hair loss and involves immune system disruptions.

Hair color is influenced by genetics and can indicate certain health conditions.

Alopecia areata is an autoimmune condition causing hair loss, linked to genetic factors and immune system issues, with no cure yet.

The microbiome may be linked to hair loss and could be a target for new treatments.

The MPV/PC ratio can help assess disease activity in alopecia areata.

Belimumab effectively reduces disease activity in lupus patients, regardless of initial serologic status.

Botulinum toxin type A significantly reduces scalp psoriasis severity compared to placebo.

The document concludes that alopecia has significant social and psychological effects, leading to a market for hair loss treatments.

The summit aimed to speed up finding treatments for alopecia areata.

The CRH/CRH-R1 system might be involved in causing lichen planus.

The document explains various skin conditions and their treatments.

The document concludes that Cutaneous Lupus Erythematosus has different forms, is influenced by genetic and environmental factors, and can be treated with various medications, but more targeted therapies are needed.

Cicatricial alopecia, a permanent hair loss condition, is mainly caused by damage to specific hair follicle stem cells and abnormal immune responses, with gene regulator PPAR-y and lipid metabolism disorders playing significant roles.